Back to Treatments

Treatment

Lenvatinib + Pembrolizumab

1
Conditions
15
Trials
5,000
Participants
35%
Average Safety

Condition Evidence

Uterine cancer

15 trials · 5,000 participants

65% effectiveness · 35% safety
Lenvatinib + Pembrolizumab | DFDA